Seegene Inc (096530) - Total Assets
Based on the latest financial reports, Seegene Inc (096530) holds total assets worth ₩1.22 Trillion KRW (≈ $825.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Seegene Inc (096530) shareholders funds for net asset value and shareholders' equity analysis.
Seegene Inc - Total Assets Trend (2012–2024)
This chart illustrates how Seegene Inc's total assets have evolved over time, based on quarterly financial data.
Seegene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Seegene Inc's total assets of ₩1.22 Trillion consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 21.6% |
| Accounts Receivable | ₩87.89 Billion | 7.3% |
| Inventory | ₩109.37 Billion | 9.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩25.77 Billion | 2.1% |
| Goodwill | ₩7.23 Billion | 0.6% |
Asset Composition Trend (2012–2024)
This chart illustrates how Seegene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Seegene Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seegene Inc's current assets represent 61.9% of total assets in 2024, a decrease from 62.9% in 2012.
- Cash Position: Cash and equivalents constituted 21.6% of total assets in 2024, up from 5.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 9.1% of total assets.
Seegene Inc Competitors by Total Assets
Key competitors of Seegene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Seegene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.83 | 4.91 | 2.09 |
| Quick Ratio | 4.28 | 4.15 | 1.72 |
| Cash Ratio | 0.00 | 1.39 | 0.00 |
| Working Capital | ₩611.65 Billion | ₩606.29 Billion | ₩407.58 Billion |
Seegene Inc - Advanced Valuation Insights
This section examines the relationship between Seegene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | ₩1.21 Trillion |
| Market Capitalization | $767.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seegene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Seegene Inc's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Seegene Inc (2012–2024)
The table below shows the annual total assets of Seegene Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.21 Trillion ≈ $816.80 Million |
-3.69% |
| 2023-12-31 | ₩1.25 Trillion ≈ $848.09 Million |
-10.02% |
| 2022-12-31 | ₩1.39 Trillion ≈ $942.51 Million |
-6.64% |
| 2021-12-31 | ₩1.49 Trillion ≈ $1.01 Billion |
+36.10% |
| 2020-12-31 | ₩1.09 Trillion ≈ $741.78 Million |
+459.27% |
| 2019-12-31 | ₩195.72 Billion ≈ $132.63 Million |
+19.48% |
| 2018-12-31 | ₩163.81 Billion ≈ $111.01 Million |
-0.63% |
| 2017-12-31 | ₩164.84 Billion ≈ $111.71 Million |
-20.60% |
| 2016-12-31 | ₩207.62 Billion ≈ $140.70 Million |
+6.99% |
| 2015-12-31 | ₩194.05 Billion ≈ $131.50 Million |
+40.15% |
| 2014-12-31 | ₩138.45 Billion ≈ $93.83 Million |
+7.30% |
| 2013-12-31 | ₩129.04 Billion ≈ $87.45 Million |
+54.32% |
| 2012-12-31 | ₩83.62 Billion ≈ $56.67 Million |
-- |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more